Dengue is the world's most prevalent and important arboviral disease. More than 50% of the
world's population lives at daily risk of infection and it is estimated more than 95 million …

Dengue is a major global public health problem requiring a safe and efficacious vaccine as
the foundation of a comprehensive countermeasure strategy. Despite decades of attempts …

Dengue is a highly endemic infectious disease of the tropical countries and is rapidly
becoming a global burden. It is caused by any of the 4 serotypes of dengue virus and is …

In the last century, vaccination has been the most effective medical intervention to reduce
death and morbidity caused by infectious diseases. It is believed that vaccines save at least …

Dengue virus poses a major threat to global public health: two-thirds of the world's
population is now at risk from infection by this mosquito-borne virus. Dengue virus causes a …

Dengue vaccine development has reached a major milestone with the initiation, in 2010, of
the first phase III clinical trial to investigate the Sanofi Pasteur CYD tetravalent dengue …

Dengue virus (DENV) is a human pathogen with a large impact on public health. Although
no vaccine against DENV is currently licensed, a recombinant vaccine—chimeric yellow …

Dengue viruses (DENV), West Nile virus (WNV) and Japanese encephalitis virus (JEV) are
major global health and growing medical problems. While a live-attenuated vaccine exists …

Sanofi Pasteur has developed a recombinant, live-attenuated, tetravalent dengue vaccine
(CYD-TDV) that is in late-stage development. The present review summarizes the different …

Dengue is the most common arboviral disease caused by one of four distinct but closely
related dengue viruses (DENV) and places significant economic and public health burdens …